Variable	6 weeks before the onset		3 weeks before the onset		Onset
	Rate of change	<i>P</i> to the onset	Rate of change	P to the onset	Rate of change
WBC, /µL	0.81 (0.67–1.04)	а	0.74 (0.62–1.25)	NS	0.99 (0.65–1.40)
Hb, g/dL	1.09 (1.03–1.16)	NS	1.06 (1.00–1.31)	а	1.19 (1.04–1.37)
Plt, /µL	0.77 (0.51-0.96)	NS	0.79 (0.47–1.04)	NS	0.70 (0.56–0.83)
ANC, /µL	0.77 (0.56–1.22)	0.047 ^b	0.79 (0.49–1.67)	NS	1.20 (0.66–1.74)
RNC, %	1.01 (0.75–1.14)	0.047 ^b	0.96 (0.78–1.40)	NS	1.15 (1.00–1.29)
ALC, /µL	0.91 (0.64–1.39)	0.047 ^b	0.94 (0.64–1.25)	а	0.63 (0.52-1.06)
RLC, %	1.31 (0.77–1.92)	с	1.35 (0.47–1.87)	NS	0.76 (0.57–1.29)
AEC, /µL	1.75 (1.08–3.13)	0.047 ^b	1.95 (0.82–3.73)	а	0.85 (0.17-2.06)
REC, %	2.73 (1.25-3.91)	0.047 ^b	2.67 (1.18-3.48)	а	1.43 (0.12–2.13)
AMC, /µL	0.61 (0.24–1.26)	NS	0.81 (0.42–1.26)	NS	0.65 (0.44–1.63)
RMC, %	1.06 (0.87–1.49)	NS	0.96 (0.70-1.24)	NS	0.80 (0.53-1.38)
NLR	0.87 (0.41-1.56)	0.047 ^b	0.72 (0.45-3.09)	NS	1.66 (0.74–2.65)
dNLR	0.97 (0.90-1.00)	с	1.02 (0.91-1.08)	NS	1.05 (0.93–1.11)
NER	0.39 (0.17-0.78)	0.047 ^b	0.41 (0.21–9.33)	с	0.79 (0.36-15.60
PLR	0.73 (0.43–1.59)	с	0.78 (0.47-1.46)	NS	0.86 (0.63-1.57)
Alb, g/dL	1.21 (0.95–1.53)	NS	1.24 (0.88–1.50)	0.047 ^b	1.38 (1.00–1.78)
AST, U/L	1.02 (0.90-1.30)	а	0.96 (0.76–1.37)	NS	0.90 (0.72-1.01)
ALT, U/L	0.95 (0.52-1.17)	а	0.89 (0.47–1.39)	с	1.11 (0.66–1.83)
ALP, U/L	0.95 (0.63-1.36)	NS	1.04 (0.63–1.28)	а	1.39 (0.81–1.74)
BUN, mg/dL	1.10 (0.98–1.24)	NS	1.14 (0.97–1.35)	с	1.47 (1.08–1.93)
Cr, mg/dL	1.17 (1.03–1.26)	NS	1.12 (1.07–1.19)	NS	1.17 (1.03–1.51)
eGFR, mL/min/1.73 m ²	0.84 (0.77-0.97)	NS	0.87 (0.82-0.92)	NS	0.84 (0.65–0.97)
Na, mEq/L	1.00 (0.98–1.02)	а	1.00 (0.97–1.02)	а	0.95 (0.92-1.00)
K, mEq/L	1.05 (0.95–1.11)	a	1.02 (0.95–1.07)	0.047 ^b	1.14 (1.07–1.27)
Cl, mEq/L	1.00 (0.98–1.04)	а	1.01 (0.94–1.04)	а	0.92 (0.88–1.01)
Ca, mg/dL	0.96 (0.9–1.04)	NS	0.99 (0.91–1.03)	NS	1.06 (0.98–1.06)
LDH, U/L	1.05 (0.84–1.13)	NS	0.91 (0.82–1.14)	NS	1.0 (0.81–1.11)
CRP, mg/dL	0.09 (0.03-1.6)	NS	0.63 (0.02–1.78)	NS	0.5 (0.04–1.43)
FT4, ng/dL	1.13 (0.98–1.18)	NS	1.04 (1.02–1.26)	NS	1.13 (0.95–1.36)
TSH, μIU/mL	1.58 (0.81-3.56)	NS	NA	NA	0.77 (0.13-2.96)

Values are expressed as median (range).

ICI-T1DM, immune-checkpoint inhibitor-induced type 1 diabetes mellitus; WBC, white blood cell; NS, not significant; Hb, hemoglobin; Plt, platelet count; ANC, absolute neutrophil count; RNC, relative neutrophil count; ALC, absolute lymphocyte count; RLC, relative lymphocyte count; AEC, absolute eosinophil count; REC, relative eosinophil count; AMC, absolute monocyte count; RMC, relative monocyte count; NLR, neutrophil-lymphocyte rate; dNLR, derived NLR; NER, neutrophil-eosinophil rate; PLR, platelet-lymphocyte rate; Alb, albumin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular filtration rate; Na, sodium; K, potassium; Cl, chloride; Ca, calcium; LDH, lactate dehydrogenase; CRP, C-reactive protein; FT4, free thyroxine; TSH, thyrotropin; NA, not applicable. ${}^{a}P=0.062$ and P=0.031, after and before Bonferroni correction, respectively. ${}^{b}P$ values <0.05 after Bonferroni correction were considered as significant; ${}^{c}P=0.094$, and P=0.047, after and before Bonferroni correction, respectively.